Global Cancer Tubulin Inhibitors Market Research Report 2012-2023

1 Market Overview

1.1 Objectives of Research

1.1.1 Definition

1.1.2 Specifications

1.2 Market Segment

1.2.1 by Type

1.2.1.1 Docetaxel

1.2.1.2 Trastuzumab Emtansine

1.2.1.3 Abraxane

1.2.1.4 Brentuximab Vedotin

1.2.1.5 Cabazitaxel

1.2.2 by Application

1.2.2.1 Non Small Cell Lung Cancer

1.2.2.2 Prostate Cancer

1.2.2.3 Breast Cancer

1.2.2.4 Colorectal Cancer

1.2.2.5 Ovarian Cancer

1.2.3 by Regions

2 Industry Chain

2.1 Industry Chain Structure

2.2 Upstream

2.3 Market

2.3.1 SWOT

2.3.2 Dynamics

3 Environmental Analysis

3.1 Policy

3.2 Economic

3.3 Technology

3.4 Market Entry

4 Market Segmentation by Type

4.1 Market Size

4.1.1 Docetaxel Market, 2012-2017

4.1.2 Trastuzumab Emtansine Market, 2012-2017

4.1.3 Abraxane Market, 2012-2017

4.1.4 Brentuximab Vedotin Market, 2012-2017

4.1.5 Cabazitaxel Market, 2012-2017

4.2 Market Forecast

4.2.1 Docetaxel Market Forecast, 2018-2023

4.2.2 Trastuzumab Emtansine Market Forecast, 2018-2023

4.2.3 Abraxane Market Forecast, 2018-2023

4.2.4 Brentuximab Vedotin Market Forecast, 2018-2023

4.2.5 Cabazitaxel Market Forecast, 2018-2023

5 Market Segmentation by Application

5.1 Market Size

5.1.1 Non Small Cell Lung Cancer Market, 2012-2017

5.1.2 Prostate Cancer Market, 2012-2017

5.1.3 Breast Cancer Market, 2012-2017

5.1.4 Colorectal Cancer Market, 2012-2017

5.1.5 Ovarian Cancer Market, 2012-2017

5.2 Market Forecast

5.2.1 Non Small Cell Lung Cancer Market Forecast, 2018-2023

5.2.2 Prostate Cancer Market Forecast, 2018-2023

5.2.3 Breast Cancer Market Forecast, 2018-2023

5.2.4 Colorectal Cancer Market Forecast, 2018-2023

5.2.5 Ovarian Cancer Market Forecast, 2018-2023

6 Market Segmentation by Region

6.1 Market Size

6.1.1 Asia-Pacific

6.1.1.1 Asia-Pacific Market, 2012-2017

6.1.1.2 Asia-Pacific Market by Type

6.1.1.3 Asia-Pacific Market by Application

6.1.2 North America

6.1.2.1 North America Market, 2012-2017

6.1.2.2 North America Market by Type

6.1.2.3 North America Market by Application

6.1.3 Europe

6.1.3.1 Europe Market, 2012-2017

6.1.3.2 Europe Market by Type

6.1.3.3 Europe Market by Application

6.1.4 South America

6.1.4.1 South America Market, 2012-2017

6.1.4.2 South America Market by Type

6.1.4.3 South America Market by Application

6.1.5 Middle East & Africa

6.1.5.1 Middle East & Africa Market, 2012-2017

6.1.5.2 Middle East & Africa Market by Type

6.1.5.3 Middle East & Africa Market by Application

6.2 Market Forecast

6.2.1 Asia-Pacific Market Forecast, 2018-2023

6.2.2 North America Market Forecast, 2018-2023

6.2.3 Europe Market Forecast, 2018-2023

6.2.4 South America Market Forecast, 2018-2023

6.2.5 Middle East & Africa Market Forecast, 2018-2023

7 Market Competitive

7.1 Global Market by Vendors

7.2 Market Concentration

7.3 Price & Factors

7.4 Marketing Channel

8 Major Vendors

8.1 Abraxis Biosciences

8.1.2 Profile

8.1.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.2 Agensys

8.2.1 Profile

8.2.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.3 Amgen

8.3.1 Profile

8.3.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.4 Celgene

8.4.1 Profile

8.4.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.5 Eagle Pharmaceuticals

8.5.1 Profile

8.5.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.6 Endocyte

8.6.1 Profile

8.6.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.7 Genentech

8.7.1 Profile

8.7.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.8 Immunogen

8.8.1 Profile

8.8.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.9 Modra Pharmaceuticals

8.9.1 Profile

8.9.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.10 Pierre Fabre

8.10.1 Profile

8.10.2 Business Performance (Sales Revenue, Cost, Gross Margin)

8.11 Roche

8.12 Sanofi-Aventis

8.13 Seattle Genetics

8.14 Tocris Bioscience

9 Conclusion

Table Products Segment of Cancer Tubulin Inhibitors

Table Docetaxel Overview

Table Trastuzumab Emtansine Overview

Table Abraxane Overview

Table Brentuximab Vedotin Overview

Table Cabazitaxel Overview

Table Global Cancer Tubulin Inhibitors Market by Type, 2011-2022 (USD Million)

Table Application Segment of Cancer Tubulin Inhibitors

Table Non Small Cell Lung Cancer Overview

Table Prostate Cancer Overview

Table Breast Cancer Overview

Table Colorectal Cancer Overview

Table Ovarian Cancer Overview

Table Global Cancer Tubulin Inhibitors Market by Application, 2011-2022 (USD Million)

Table Global Cancer Tubulin Inhibitors Market by Region, 2011-2022 (USD Million)

Table Cost of Cancer Tubulin Inhibitors

Table Market Dynamics

Table Policy of Cancer Tubulin Inhibitors

Table GDP of Major Countries

Table Docetaxel CAGR by Revenue and Volume, 2012-2017

Table Trastuzumab Emtansine CAGR by Revenue and Volume, 2012-2017

Table Abraxane CAGR by Revenue and Volume, 2012-2017

Table Brentuximab Vedotin CAGR by Revenue and Volume, 2012-2017

Table Cabazitaxel CAGR by Revenue and Volume, 2012-2017

Table Docetaxel CAGR by Revenue and Volume, 2012-2022

Table Trastuzumab Emtansine CAGR by Revenue and Volume, 2012-2022

Table Abraxane CAGR by Revenue and Volume, 2012-2022

Table Brentuximab Vedotin CAGR by Revenue and Volume, 2012-2022

Table Cabazitaxel CAGR by Revenue and Volume, 2012-2022

Table Non Small Cell Lung Cancer CAGR by Revenue and Volume, 2012-2017

Table Prostate Cancer CAGR by Revenue and Volume, 2012-2017

Table Breast Cancer CAGR by Revenue and Volume, 2012-2017

Table Colorectal Cancer CAGR by Revenue and Volume, 2012-2017

Table Ovarian Cancer CAGR by Revenue and Volume, 2012-2017